{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:26:39Z","timestamp":1772119599113,"version":"3.50.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["2021-1-13470"],"award-info":[{"award-number":["2021-1-13470"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Epidemiol"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>There is a high need for accurate prognostic models among stage II melanoma to determine who may benefit from (neo)adjuvant systemic therapy. The Dutch Early- Stage Melanoma (D-ESMEL) study was designed to identify new prognostic features in a population-based sample of stage I\/II melanoma patients in addition to American Joint Committee of Cancer (AJCC) staging. The validation cohort of the D-ESMEL study employs a nested case-control design. Initially, controls were randomly sampled to develop prognostic that included both known and new prognostic factors to assess the additive value of new prognostic factors. As a consequence, most controls had a very thin melanoma (&lt;1.0\u00a0mm) while most cases had a thicker melanoma (&gt;2.0\u00a0mm). This resulted in insufficient variability and high weights for stage II controls when applying weighted analyses in absolute risk prediction models. Therefore, randomly sampled controls were re-matched on AJCC stage (stage IA, IB, IIA, IIB, IIC), and new stage-matched controls were collected for cases who could not be rematched. The original D-ESMEL validation cohort included 5,815 stage I\/II melanoma patients, of whom 154 developed distant metastasis (cases). 98\/154 Cases were stage II and only 24 stage II controls were included, while the stage-matched design now includes 153 stage-matched case-control sets of which 97 stage II cases and 97 stage II controls derived from a population-based cohort of 5,785 stage I\/II patients. The updated design increased the biological variability among stage II controls, balanced weights in weighted analyses and thereby facilitating reliable subgroup analyses in this clinically important subgroup.<\/jats:p>","DOI":"10.1007\/s10654-025-01337-3","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T05:03:27Z","timestamp":1768194207000},"page":"127-131","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["An extension of the validation cohort of the Dutch Early-Stage Melanoma (D-ESMEL) study for stage-specific analyses"],"prefix":"10.1007","volume":"41","author":[{"given":"Catherine","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antien L.","family":"Mooyaart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikita","family":"Hulscher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thamila","family":"Kerkour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasper","family":"Ouwerkerk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marieke W. J.","family":"Louwman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlies","family":"Wakkee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunlei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quirinus J. M.","family":"Voorham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"Bruggink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamar E. C.","family":"Nijsten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8922-6791","authenticated-orcid":false,"given":"Loes M.","family":"Hollestein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"1337_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174431","author":"C Zhou","year":"2021","unstructured":"Zhou C, Louwman M, Wakkee M, et al. Primary melanoma characteristics of metastatic disease: a nationwide cancer registry study. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13174431.","journal-title":"Cancers (Basel)"},{"issue":"10","key":"1337_CR2","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1002\/cam4.1152","volume":"6","author":"EAL Enninga","year":"2017","unstructured":"Enninga EAL, Moser JC, Weaver AL, et al. Survival of cutaneous melanoma based on sex, age, and stage in the united States, 1992\u20132011. Cancer Med. 2017;6(10):2203\u201312.","journal-title":"Cancer Med"},{"issue":"1","key":"1337_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s10654-024-01188-4","volume":"40","author":"C Zhou","year":"2025","unstructured":"Zhou C, Mooyaart AL, Kerkour T, et al. The Dutch early-stage melanoma (D-ESMEL) study: a discovery set and validation cohort to predict the absolute risk of distant metastases in stage I\/II cutaneous melanoma. Eur J Epidemiol. 2025;40(1):27\u201342. https:\/\/doi.org\/10.1007\/s10654-024-01188-4.","journal-title":"Eur J Epidemiol"},{"issue":"3","key":"1337_CR4","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.jaad.2011.10.026","volume":"67","author":"JE Frangos","year":"2012","unstructured":"Frangos JE, Duncan LM, Piris A, et al. Increased diagnosis of thin superficial spreading melanomas: a 20-year study. J Am Acad Dermatol. 2012;67(3):387\u201394. https:\/\/doi.org\/10.1016\/j.jaad.2011.10.026.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1337_CR5","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1001\/jamadermatol.2022.0139","volume":"158","author":"AS Adamson","year":"2022","unstructured":"Adamson AS, Suarez EA, Welch HG. Estimating overdiagnosis of melanoma using trends among black and white patients in the US. JAMA Dermatol. 2022;158(4):426\u201331. https:\/\/doi.org\/10.1001\/jamadermatol.2022.0139.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1337_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-024-02213-6","volume":"24","author":"B Rentroia-Pacheco","year":"2024","unstructured":"Rentroia-Pacheco B, Bellomo D, Lakeman IMM, Wakkee M, Hollestein LM, van Klaveren D. Weighted metrics are required when evaluating the performance of prediction models in nested case-control studies. BMC Med Res Methodol. 2024;24(1):115. https:\/\/doi.org\/10.1186\/s12874-024-02213-6.","journal-title":"BMC Med Res Methodol"},{"issue":"11","key":"1337_CR7","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1038\/s41591-023-02583-2","volume":"29","author":"JM Kirkwood","year":"2023","unstructured":"Kirkwood JM, Del Vecchio M, Weber J, et al. Adjuvant nivolumab in resected stage IIB\/C melanoma: primary results from the randomized, phase 3 checkmate 76K trial. Nat Med. 2023;29(11):2835\u201343. https:\/\/doi.org\/10.1038\/s41591-023-02583-2.","journal-title":"Nat Med"},{"issue":"14","key":"1337_CR8","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1200\/JCO.23.02355","volume":"42","author":"JJ Luke","year":"2024","unstructured":"Luke JJ, Ascierto PA, Khattak MA, et al. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: final analysis of distant Metastasis-Free survival in the phase III KEYNOTE-716 study. J Clin Oncol. 2024;42(14):1619\u201324. https:\/\/doi.org\/10.1200\/JCO.23.02355.","journal-title":"J Clin Oncol"},{"key":"1337_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16152690","author":"GM Vargas","year":"2024","unstructured":"Vargas GM, Farooq MS, Karakousis GC. Adjuvant therapy for high-risk stage II melanoma: current paradigms in management and future directions. Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/cancers16152690.","journal-title":"Cancers (Basel)"},{"key":"1337_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.05.003","volume":"189","author":"R Lee","year":"2023","unstructured":"Lee R, Mandala M, Long GV, et al. Adjuvant therapy for stage II melanoma: the need for further studies. Eur J Cancer. 2023;189:112914. https:\/\/doi.org\/10.1016\/j.ejca.2023.05.003.","journal-title":"Eur J Cancer"}],"container-title":["European Journal of Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10654-025-01337-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10654-025-01337-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10654-025-01337-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T05:05:48Z","timestamp":1770354348000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10654-025-01337-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1337"],"URL":"https:\/\/doi.org\/10.1007\/s10654-025-01337-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7797700\/v1","asserted-by":"object"}]},"ISSN":["0393-2990","1573-7284"],"issn-type":[{"value":"0393-2990","type":"print"},{"value":"1573-7284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"7 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethical approval was obtained from the scientific committees of Erasmus MC (MEC-2018-1738), the Dutch Nationwide Pathology Databank, and the Netherlands Cancer Registry.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The use of leftover diagnostic tissue samples for scientific research is based on the \u2018no objection\u2019 principle, as outlined in the Code of Conduct for Health Research by the Committee on Regulation of Health Research.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}